Ultrasonographic and Laboratory Markers of Metabolic and Cardiovascular Disease Risk in Obese Women with Polycystic Ovary Syndrome

    February 2012
    Lucimara Facio Nobre Zueff, Wellington P. Martins, Carolina Sales Vieira, Rui Alberto Ferriani
    Studysummary Among obese women potentially eligible for combined oral contraceptives, this study observed a higher frequency of non-alcoholic fatty liver disease in those with polycystic ovary syndrome.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on obgyn.onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Increased Androgen Bioavailability Is Associated With Non-Alcoholic Fatty Liver Disease In Women With Polycystic Ovary Syndrome Human Reproduction · 2009
    2. The Evaluation of Endothelial Function with Flow-Mediated Dilatation and Carotid Intima Media Thickness in Young Nonobese Polycystic Ovary Syndrome Patients; Existence of Insulin Resistance Alone May Not Represent an Adequate Condition for Deterioration of Endothelial Function Fertility and Sterility · 2008
    3. Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred Because of Clinical Hyperandrogenism The Journal of Clinical Endocrinology and Metabolism · 2006
    4. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome Fertility and Sterility · 2004
    5. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS) Human Reproduction · 2003
    6. The Pathophysiology of Polycystic Ovary Syndrome Clinical endocrinology · 2003